AllSci News
Beacon's laru-zova becomes first XLRP gene therapy to meet pivotal trial primary endpoint
Beacon Therapeutics' laruparetigene zovaparvovec met the primary endpoint in the pivotal VISTA trial in X-linked retinitis pigmentosa (XLRP), with both...
Xenon files azetukalner NDA for focal seizures as KV7 revival, pauses psychiatry trials
Xenon Pharmaceuticals (Nasdaq: XENE) has submitted a New Drug Application (NDA) to the US FDA for azetukalner, a KV7 potassium channel opener, seeking...
Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria
CUE-221 (UB-221), a dual-mechanism anti-IgE monoclonal antibody being developed by Boston-based Cue Biopharma (Nasdaq: CUE), met both its primary and key...
China targets 25% of global first-in-class drugs by 2030 in new pharma five-year-plan
China has set a target for domestically originated first-in-class (FIC) drugs to account for at least 25% of the global total by 2030, alongside annual...
Hansoh's TYK2 inhibitor HS-10374 meets Phase III endpoints in moderate-to-severe psoriasis
Hansoh Pharmaceutical Group (HKEX: 3692) has reported that HS-10374, its oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, met co-primary...
Antengene launches pivotal Phase III trial of ATG-022 in third-line gastric cancer
Antengene Corporation Ltd (SEHK: 6996.HK) has dosed the first patient in the pivotal Phase III CLINCH-3 study of its CLDN18.2-targeting antibody-drug...
Abbisko's lavengratinib achieves 100% responder rate in early achondroplasia trial
Preliminary Phase II data from Shanghai-based Abbisko Therapeutics (HKEX: 02256) suggest that lavengratinib (ABSK061), its oral FGFR2/3 inhibitor, produces...
Telix acquires ITM Isotope Technologies for USD 1.65b to secure radioisotope supply chain
Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for USD 1.65 billion upfront...
US Treasury reportedly drafting rules to preserve pharma licensing deals with China
The US Treasury Department is drafting rules that would largely preserve American pharmaceutical companies' ability to license drugs from Chinese...
Novo acquires three early-stage obesity programs from Columbia-linked Kallyope
Novo Nordisk (NYSE: NVO) has reportedly agreed to acquire three early-stage obesity drug programs from New York-based Kallyope, Inc., according to a...
Electra raises USD 350m IPO to push sHLH antibody toward registration
South San Francisco-based Electra Therapeutics, Inc. (Nasdaq: ETRA), developing a signal regulatory protein (SIRP)-targeted antibody for a rare...
GOA Therapeutics emerges from stealth with USD 15.5m for alcohol-poisoning therapy
Santa Monica, California-based GOA Therapeutics Corporation has emerged from stealth with USD 15.5 million in cumulative funding and disclosed its lead drug...
FDA approves Ibtrozi label update with 49.7-month DOR in ROS1 NSCLC
The US FDA has approved a supplemental New Drug Application for Ibtrozi (taletrectinib), updating the label for New York-based Nuvation Bio (NYSE: NUVB)'s...
Nobel laureate-founded MasterSwitch secures NIH backing for HNF4α liver therapy
MasterSwitch Bio has received a USD 1.19 million SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases to advance an HNF4α...
Airway Therapeutics gets NHLBI grant for zelpultide alfa BPD trial
Airway Therapeutics, Inc. has received a USD 1.9 million NHLBI R44 SBIR grant to fund a Phase IIb/III trial of zelpultide alfa, a recombinant human...
The AllSci Brief
Free, systematic R&D and deal news. Daily.